Summary
AbbVie Inc. reported solid financial results for the first quarter of 2014, demonstrating year-over-year growth in key areas. Net sales increased by 5% to $4.56 billion, driven primarily by the sustained strength of its flagship product, HUMIRA, which saw an 18% increase in global sales. This growth was further bolstered by double-digit sales increases from products like Synthroid, Creon, and Duodopa. Despite facing headwinds from the loss of exclusivity in its lipid franchise, which resulted in a significant revenue decline, AbbVie managed to maintain profitability, reporting diluted earnings per share of $0.61, consistent with the prior year. The company also continued to invest significantly in its research and development pipeline, with R&D expenses rising by 22% to $772 million, underscoring its commitment to future growth through innovation. AbbVie's strong operational performance and strategic R&D investments position it well for continued success.
Financial Highlights
49 data points| Revenue | $4.56B |
| Cost of Revenue | $1.10B |
| Gross Profit | $3.46B |
| SG&A Expenses | $1.34B |
| Operating Expenses | $3.21B |
| Operating Income | $1.35B |
| Interest Expense | $70.00M |
| Net Income | $980.00M |
| EPS (Basic) | $0.61 |
| EPS (Diluted) | $0.61 |
| Shares Outstanding (Basic) | 1.59B |
| Shares Outstanding (Diluted) | 1.61B |
Key Highlights
- 1Net sales grew 5% to $4.56 billion in Q1 2014.
- 2HUMIRA sales increased 18% globally to $2.64 billion, driven by continued strength across therapeutic categories and geographies.
- 3R&D expenses increased 22% to $772 million, reflecting investment in pipeline development and new indications for existing products.
- 4Diluted earnings per share remained stable at $0.61 compared to Q1 2013.
- 5Gross profit margin improved to 76% from 73% in the prior year, aided by product mix and operational efficiencies.
- 6AbbVie repurchased approximately $250 million of its stock during the quarter under its $1.5 billion share repurchase program.